Muller & Phipps India Ltd
- Market cap
- ₹ 12 Cr.
- P/E
- 170.8x
- 52-week range
- 188.1 – 264
- Dividend yield
- 0%
- Sector
- Commercial Services & Supplies
- Industry
- Trading & Distributors
- Listed on
- BSE
About
Muller and Phipps (India) Limited is an India-based company, which is engaged in the marketing of its own brands in the dental and skin care segments under the brand names of Cavisan and Nixoderm. The Company is engaged in marketing of over-the-counter medical preparation and home care products. Its products include Cavisan - Medicated Dental Cream, Cavifast - Medicated Dental Gel, Cavisan - Gum Astringent and Nixoderm. The Company's subsidiaries include Muller and Phipps (Industrial Services) Limited and Muller and Phipps Agencies Limited. Muller and Phipps (Industrial Services) Limited is engaged in India as indenting agents.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Trading & Distributors: 197 companies →Muller & Phipps India Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)170.8 against a typical 28.5: pricier than most peers (1st = cheapest).161st of 186
- Sales growth+60.9% against a typical −2.4% from a year earlier.26th of 143
- Profit growth−84.3% against a typical −13.1% from a year earlier.89th of 124
- Share price, 3 months−10.6% against a typical −4.9%.111th of 169
- Size₹ 12.2 Cr. market value against a typical ₹ 26.8 Cr. (1st = largest).130th of 183
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Expenses | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 2 |
| Operating Profit | 0 | −0 | −0 | 0 | −0 | −0 | −1 | −0 | −0 | −0 | −0 | −0 |
| OPM % | 11.8% | −14.5% | −39.2% | 0.7% | −23.1% | −12.6% | −30.6% | −38% | −3.9% | −30.2% | −25.3% | −12.2% |
| Other Income | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | −0 | 0 | 0 | −0 | −0 | −0 | 1 | −0 | −0 | −0 | 0 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 0 | −0 | 0 | 0 | −0 | −0 | −0 | 1 | −0 | −0 | −0 | 0 |
| EPS in Rs | 2.88 | −0.8 | 4.8 | 0.96 | −3.68 | −1.92 | −7.52 | 11.2 | −0.48 | −6.24 | −5.28 | 1.76 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 5%
- 5 Years
- 7%
- 3 Years
- 13%
- TTM
- 16%
- 10 Years
- 3%
- 5 Years
- —
- 3 Years
- —
- TTM
- −433%
- 10 Years
- 10%
- 5 Years
- 10%
- 3 Years
- 7%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Muller & Phipps India Ltd | ₹ 195.00 | ₹ 12 Cr. | 170.8x | — | — | — |
| MedPlus Health Services | ₹ 597.45 | ₹ 7,182 Cr. | 43.7x | 4.9x | 11.8% | 3.2% |
| Novelix Pharmaceuticals | ₹ 60.99 | ₹ 166 Cr. | 52.3x | 2.9x | 8% | 1.9% |
Management
- Sanjay Soman
- Practicing Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.